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One Minute Ophthalmology
Photopsia and visual loss in a patient
with lung cancer
Case
A 68‑year‑old Caucasian male with a history of lung carcinoma with
metastasis to bone and lymph nodes, treated with 1.5 months of
checkpoint inhibitor (CPI) pembrolizumab (antiprogrammed cell death
protein‑1 antibody), noted photopsia and decreased visual acuity in
the left eye (OS) over 2 months. On examination, visual acuity was
20/25 in the right eye (OD) and 20/80 OS. Fundus evaluation revealed
juxtapapillary subtle yellow choroidal discoloration with associated
subretinal fluid (SRF) OS. The right eye was unremarkable.

What is your next step?
A.
B.
C.
D.

Apply plaque radiotherapy
Perform fine needle aspiration biopsy
Apply photodynamic therapy
Continue pembrolizumab

Findings
Fundoscopic examination OS revealed an ill‑defined, juxtapapillary,
amelanotic choroidal mass with surrounding SRF involving the
macula [Fig. 1a]. The lesion demonstrated indiscrete margins,
measuring approximately 10 mm in diameter and 2.2 mm in
ultrasonographic thickness [Fig. 1b]. By optical coherence tomography,
the choroid was thickened and demonstrated a “lumpy, bumpy”
surface configuration, suggestive of choroidal metastasis [Fig. 1c].
These features were suggestive of a partial response to pembrolizumab.
The right eye was normal.
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Correct answer: D

Discussion
Choroidal metastasis is a serious finding, associated with only 24%
survival at 5 years.[1] The most common primary tumor sites include
cancers of the breast (37%), lung (27%), kidney (4%), gastrointestinal
tract (4%), and cutaneous melanoma (2%).[1] Metastases with best 1‑year
survival originate from lung carcinoid (92%), cutaneous melanoma (70%),
and breast cancer (66%), while those with the poorest 1‑year survival
exhibit thyroid (35%), gastrointestinal (33%), and pancreatic (25%
6‑month survival) origin.[1] Immunoinhibitory ligands are targeted by
CPIs, upregulating the immune system to attack tumor. Ocular side
effects include uveitis in 1% of patients; systemic side effects include
lymphocytopenia and hepatitis.[2,3] Patients with systemic cancer and new
ocular symptoms should have detailed ocular evaluation to determine
the cause, such as medication‑related, paraneoplastic syndrome, or
metastatic disease.[2]
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Figure 1: A 68-year-old Caucasian male presented with flashes
and decreased vision in the left eye and was found to have (a) an
ill-defined choroidal mass on fundoscopy of the left eye. (b) B scan
ultrasonography of the left eye revealed a small amount of subretinal
fluid inferiorly. (c) Optical coherence tomography revealed thickening
of the choroid and subretinal fluid beneath the fovea
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